Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
From MaRDI portal
Publication:70258
DOI10.2307/2531628zbMath0715.62242OpenAlexW2076108528WikidataQ48901121 ScholiaQ48901121MaRDI QIDQ70258
John O'Quigley, Lloyd Fisher, John O'Quigley, Lloyd Fisher, Margaret S. Pepe
Publication date: March 1990
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.2307/2531628
Related Items (only showing first 100 items - show all)
Target toxicity design for phase I dose-finding ⋮ A system for determining maximum tolerated dose in clinical trial ⋮ PA‐CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials ⋮ DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses ⋮ A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes ⋮ Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics ⋮ Performance Measures in Dose‐Finding Experiments ⋮ Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information ⋮ Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies ⋮ A continual reassessment method without undue risk of toxicity ⋮ A modified Huber loss function for continual reassessment methods in clinical trials ⋮ Retrospective Analysis of Sequential Dose‐Finding Designs ⋮ Bias induced by adaptive dose-finding designs ⋮ Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data ⋮ Patient-specific dose finding in phase I clinical trials ⋮ Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations ⋮ A note on continual reassessment method ⋮ Optimal sequential designs in phase I studies ⋮ Continual Reassessment Method for Partial Ordering ⋮ Designs for Single- or Multiple-Agent Phase I Trials ⋮ Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design ⋮ Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials ⋮ An application of reinforced urn processes to determining maximum tolerated dose ⋮ Review of Statistical Treatment for Oncology Dose-Escalation Trial with Prolonged Evaluation Window or Fast Enrollment ⋮ SEQUENTIAL METHODS IN CLINICAL TRIALS* ⋮ Designs foe phase i cancer clinical trials with differentiation of graded toxicity ⋮ A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents ⋮ The role of minimal sets in dose finding studies ⋮ Efficiency of bridging between related dose finding studies ⋮ Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial ⋮ Sequential method of estimating the LD50 using a modified up-and-down rule ⋮ A new design of the continual reassessment method ⋮ A novel framework to estimate multidimensional minimum effective doses using asymmetric posterior gain and \(\epsilon\)-tapering ⋮ Impact of different model structure and prior distribution in continual reassessment method ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ Methodology and application of adaptive and sequential approaches in contemporary clinical trials ⋮ Number of patients per cohort and sample size considerations using dose escalation with overdose control ⋮ A Bayesian adaptive dose-finding algorithm for balancing individual- and population-level ethics in Phase I clinical trials ⋮ Unnamed Item ⋮ Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Continual reassessment and related dose-finding designs ⋮ Dose finding with escalation with overdose control (EWOC) in cancer clinical trials ⋮ Bayesian models and decision algorithms for complex early phase clinical trials ⋮ Approximate dynamic programming and its applications to the design of Phase I cancer trials ⋮ A new look at evaluating MTD designs in cancer research ⋮ A note on the robustness of the continual reassessment method ⋮ Adaptive Bayesian compound designs for dose finding studies ⋮ Bayesian phase I/II adaptively randomized oncology trials with combined drugs ⋮ The adaptive accelerated biased coin design for phase I clinical trials ⋮ Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity ⋮ Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Cumulative cohort design for dose-finding ⋮ A Statistical Framework for Quantile Equivalence Clinical Trials with Application to Pharmacokinetic Studies that Bridge from HIV‐Infected Adults to Children ⋮ Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors ⋮ Dynamic calibration of pharmacokinetic parameters in dose-finding studies ⋮ Continual reassessment method with multiple toxicity constraints ⋮ Book Reviews ⋮ On the consistency of the continual reassessment method with multiple toxicity constraints ⋮ Incorporating Individual and Collective Ethics into Phase I Cancer Trial Designs ⋮ A class of designs for Phase I cancer clinical trials combining Bayesian and likelihood approaches ⋮ Design efficiency in dose finding studies ⋮ Adaptive designs for selecting drug combinations based on efficacy-toxicity response ⋮ Convergence properties of sequential Bayesian \(D\)-optimal designs ⋮ Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials ⋮ Simple benchmark for complex dose finding studies ⋮ Optimal adaptive generalized Pólya urn design for multi-arm clinical trials ⋮ The treatment versus experimentation dilemma in dose finding studies ⋮ Dose-Finding Based on Efficacy-Toxicity Trade-Offs ⋮ A Semiparametric Sequential Algorithm for Estimation of Dose–Response Curve ⋮ Unnamed Item ⋮ Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress ⋮ Ethical considerations concerning treatment allocation in drug development trials ⋮ A Curve‐Free Method for Phase I Clinical Trials ⋮ The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach ⋮ Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities ⋮ Theoretical study of the continual reassessment method ⋮ Adaptive designs for dose-finding based on efficacy-toxicity response ⋮ Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach ⋮ Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses ⋮ Statistical Properties of a Modified Accelerated Design for Phase I Cancer Clinical Trials ⋮ A bayesian predictive approach to sequential search for an optimal dose: Parametric and nonparametric models ⋮ Multivariate Markov models for the conditional probability of toxicity in phase II trials ⋮ Incoherent dose-escalation in phase I trials using the escalation with overdose control approach ⋮ The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach ⋮ A Hierarchical Bayesian Design for Phase I Trials of Novel Combinations of Cancer Therapeutic Agents ⋮ Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers ⋮ Sequential Methods in Multi-Arm Clinical Trials ⋮ escalation ⋮ Analysis of ``learn-as-you-go (LAGO) studies ⋮ Unifying CRM and EWOC designs for phase I cancer clinical trials ⋮ Dose-Finding Based on Feasibility and Toxicity in T-cell Infusion Trials ⋮ Dose-Finding Designs for HIV Studies ⋮ Monitoring the Rates of Composite Events with Censored Data in Phase II Clinical Trials ⋮ On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance ⋮ Curve-Free and Model-Based Continual Reassessment Method Designs ⋮ A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method ⋮ Directed Walk Designs for Dose-Response Problems with Competing Failure Modes ⋮ On optimal designs for clinical trials: an updated review
This page was built for publication: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
